Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 121M | 116M | 113M | 98M | 91M |
| Gross Profit | 10M | 93M | 92M | 81M | 75M |
| Operating Income | 20M | 20M | 25M | 34M | 33M |
| EBITDA | 83M | 64M | 66M | 67M | 64M |
| Net Income | 5M | -3M | 8M | 22M | 22M |
| EPS (Diluted) | — | — | — | — | — |
Real Estate
Live Price
Offline$17.93
-0.58% today
1Y Change
+6.16%
Window
Jun 25, 2025 → Jun 15, 2026
Coverage: 244 bars · Jun 25, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Community Healthcare Trust Inc. (CHCT) is a Real Estate stock with a market cap of $500.00M and listed on NYSE. The stock last traded around $17.93 and up 6.2% across the available one-year price window (Jun 25, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +4.7%, EPS growth of +133.7%, a dividend yield of 10.7%. What stands out right now is revenue +4.7%, EPS +133.7%, free cash flow +64.8% with operating margin 39.8% and ROIC 4.5%. The dividend matters to the case here, with a current yield around 10.7%. Valuation already assumes a fairly strong business story at P/E 78.6 and price/sales 4.1. Stock Foundry combines CHCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Real Estate peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHCT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHCT Max Drawdown
-23.94%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CHCT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$90.6M
-7.3% YoY
FY Net Income
$22.5M
+2.1% YoY
Free Cash Flow
$49.1M
-1.6% YoY
Revenue Growth
+4.7%
EPS Growth
+133.7%
Gross Margin
62.7%
Net Margin
5.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 121M | 116M | 113M | 98M | 91M |
| Gross Profit | 10M | 93M | 92M | 81M | 75M |
| Operating Income | 20M | 20M | 25M | 34M | 33M |
| EBITDA | 83M | 64M | 66M | 67M | 64M |
| Net Income | 5M | -3M | 8M | 22M | 22M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 4M | 3M | 11M | 2M |
| Total Assets | 991M | 993M | 945M | 876M | 754M |
| Total Liabilities | 561M | 517M | 432M | 380M | 292M |
| Shareholder Equity | 429M | 476M | 513M | 497M | 462M |
| Total Debt | 536M | 490M | 412M | 357M | 269M |
| Net Debt | 533M | 486M | 409M | 346M | 267M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
56M
-6.5% YoY
Capital Expenditures
7M
+30.4% YoY
Free Cash Flow
49M
-1.6% YoY
Key ratios
Gross Margin
62.7%
Operating Margin
39.8%
Net Margin
5.0%
ROE
1.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.